Institute of Microbiology, Lausanne University Hospital, 419236University of Lausanne, Switzerland.
Antivir Chem Chemother. 2021 Jan-Dec;29:20402066211061063. doi: 10.1177/20402066211061063.
Severe acute respiratory syndrome coronavirus 2 is an RNA virus currently causing a pandemic. Due to errors during replication, mutations can occur and result in cell adaptation by the virus or in the rise of new variants. This can change the attachment receptors' usage, result in different morphology of plaques, and can affect as well antiviral development. Indeed, a molecule can be active on laboratory strains but not necessarily on circulating strains or be effective only against some viral variants. Experiments with clinical samples with limited cell adaptation should be performed to confirm the efficiency of drugs of interest. In this protocol, we present a method to culture severe acute respiratory syndrome coronavirus 2 from nasopharyngeal swabs, obtain a high viral titer while limiting cell adaptation, and assess antiviral efficiency.
严重急性呼吸综合征冠状病毒 2 是一种 RNA 病毒,目前正在引发大流行。由于复制过程中的错误,病毒可能会发生突变,从而导致细胞适应或新变体的出现。这可能会改变附着受体的使用,导致斑块形态的不同,并且还可能影响抗病毒药物的开发。事实上,一种分子可能对实验室株有效,但对流行株不一定有效,或者仅对某些病毒变异株有效。应该使用临床样本进行有限细胞适应的实验来确认感兴趣药物的效率。在本方案中,我们介绍了一种从鼻咽拭子中培养严重急性呼吸综合征冠状病毒 2 的方法,在限制细胞适应的同时获得高病毒滴度,并评估抗病毒效率。